Immunovant, Inc. (IMVT)
NMS · Healthcare · Biotechnology
$33.62
+2.25%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$6.90B
Shares Outstanding
205.3M
Exchange
NMS
Currency
USD
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -127.2M | -131.8M | -114.4M | -159.6M |
| Net Income | -120.6M | -126.5M | -110.6M | -147.9M |
| Diluted EPS | $-0.71 | $-0.73 | $-0.61 | $-0.73 |
Annual Financials
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -208.3M | -270.2M | -438.2M | -532.9M |
| Net Income | -211.0M | -259.3M | -413.8M | -505.6M |
| Diluted EPS | $-1.71 | $-1.88 | $-2.73 | $nan |